 | Up a level |
Journal Article
Andersson, E. I., Puetzer, S., Yadav, B., Dufva, O., Khan, S., He, L., Sellner, L., Schrader, A., Crispatzu, G., Oles, M., Zhang, H., Adnan-Awad, S., Lagstrom, S., Bellanger, D., Mpindi, J. P., Eldfors, S., Pemovska, T., Pietarinen, P., Lauhio, A., Tomska, K., Cuesta-Mateos, C., Faber, E., Koschmieder, S., Bruemmendorf, T. H., Kytola, S., Savolainen, E-R, Siitonen, T., Ellonen, P., Kallioniemi, O., Wennerberg, K., Ding, W., Stern, M-H, Huber, W., Anders, S., Tang, J., Aittokallio, T., Zenz, T., Herling, M. and Mustjoki, S. (2018). Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia, 32 (3). S. 774 - 788. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Dietrich, S., Pircher, A., Andrulis, M. A., Peyrade, F., Wendtner, C. -M, Gaehler, A., Follows, G., Dyer, M., Elter, T., Zeiser, R., Herrmann, M., Herold, M., Dearden, C., Haferlach, T., Hallek, M., Huellein, J., Matutes, E., Duerig, J., von Kalle, C., Glimm, H., Froehling, S., Abdel-Wahab, O., Hutter, B., Steurer, M., Ho, A. and Zenz, T. (2015). Treatment of refractory hairy cell leukemia by BRAF-inhibition. Oncol. Res. Treat., 38. S. 119 - 120. BASEL: KARGER. ISSN 2296-5262
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Sellner, L., Oles, M., Anders, S., Zapatka, M., Lukas, M., Slabicki, M., Blume, C., Huellein, J., Stolz, T., Muley, C., Sill, M., Oakes, C. C., Dietrich, S., Merkel, O., Jauch, A., Schrader, A., Hensel, M., Rossi, D., Zirlik, K., Herling, M., Nguyen-Khac, F., Seiffert, M., Dreger, P., von Kalle, C., Ho, A. D., Glimm, H., Duerig, J., Ringshausen, I., Huber, W. and Zenz, T. (2014). SYSTEMATIC DRUG SENSITIVITY SCREENING IN LYMPHOID MALIGNANCIES IDENTIFIES VULNERABILITIES OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH HIGH RISK ABERRATIONS. Haematologica, 99. S. 316 - 317. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stilgenbauer, S., Schleinitz, T. Aurran, Hallek, M., Lang, F., Offner, F., Rossi, J. -F., Schroyens, W., Van Den Neste, E., Ysebaert, L., Blum, P., Hocke, J., Kress, U. U. and Zenz, T. (2015). PHASE I, FIRST-IN-HUMAN TRIAL OF BI 836826 (AN ANTI-CD37 ANTIBODY) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Haematologica, 100. S. 225 - 227. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., Denzel, T., Haebe, S., Malcikova, J., Kuglik, P., Truong, S., Patten, N., Wu, L., Oscier, D., Ibbotson, R., Gardiner, A., Tracy, I., Lin, K., Pettitt, A., Pospisilova, S., Mayer, J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2010). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24 (12). S. 2072 - 2080. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924